In comparison to the APIs for the treatment of IBD, EGCG showed a similar decrease in the release of IL-6 (to 0%) and IL-8 (to 14.2%) to the glucocorticoid (GC) Prednisolone (level 2 of severity). Here, IL6 is linked to inflammatory bowel disease.